These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 24366103)

  • 1. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
    ; Schwarzschild MA; Ascherio A; Beal MF; Cudkowicz ME; Curhan GC; Hare JM; Hooper DC; Kieburtz KD; Macklin EA; Oakes D; Rudolph A; Shoulson I; Tennis MK; Espay AJ; Gartner M; Hung A; Bwala G; Lenehan R; Encarnacion E; Ainslie M; Castillo R; Togasaki D; Barles G; Friedman JH; Niles L; Carter JH; Murray M; Goetz CG; Jaglin J; Ahmed A; Russell DS; Cotto C; Goudreau JL; Russell D; Parashos SA; Ede P; Saint-Hilaire MH; Thomas CA; James R; Stacy MA; Johnson J; Gauger L; Antonelle de Marcaida J; Thurlow S; Isaacson SH; Carvajal L; Rao J; Cook M; Hope-Porche C; McClurg L; Grasso DL; Logan R; Orme C; Ross T; Brocht AF; Constantinescu R; Sharma S; Venuto C; Weber J; Eaton K
    JAMA Neurol; 2014 Feb; 71(2):141-50. PubMed ID: 24366103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.
    ; Schwarzschild MA; Ascherio A; Casaceli C; Curhan GC; Fitzgerald R; Kamp C; Lungu C; Macklin EA; Marek K; Mozaffarian D; Oakes D; Rudolph A; Shoulson I; Videnovic A; Scott B; Gauger L; Aldred J; Bixby M; Ciccarello J; Gunzler SA; Henchcliffe C; Brodsky M; Keith K; Hauser RA; Goetz C; LeDoux MS; Hinson V; Kumar R; Espay AJ; Jimenez-Shahed J; Hunter C; Christine C; Daley A; Leehey M; de Marcaida JA; Friedman JH; Hung A; Bwala G; Litvan I; Simon DK; Simuni T; Poon C; Schiess MC; Chou K; Park A; Bhatti D; Peterson C; Criswell SR; Rosenthal L; Durphy J; Shill HA; Mehta SH; Ahmed A; Deik AF; Fang JY; Stover N; Zhang L; Dewey RB; Gerald A; Boyd JT; Houston E; Suski V; Mosovsky S; Cloud L; Shah BB; Saint-Hilaire M; James R; Zauber SE; Reich S; Shprecher D; Pahwa R; Langhammer A; LaFaver K; LeWitt PA; Kaminski P; Goudreau J; Russell D; Houghton DJ; Laroche A; Thomas K; McGraw M; Mari Z; Serrano C; Blindauer K; Rabin M; Kurlan R; Morgan JC; Soileau M; Ainslie M; Bodis-Wollner I; Schneider RB; Waters C; Ratel AS; Beck CA; Bolger P; Callahan KF; Crotty GF; Klements D; Kostrzebski M; McMahon GM; Pothier L; Waikar SS; Lang A; Mestre T
    JAMA; 2021 Sep; 326(10):926-939. PubMed ID: 34519802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial.
    Schwarzschild MA; Macklin EA; Bakshi R; Battacharyya S; Logan R; Espay AJ; Hung AY; Bwala G; Goetz CG; Russell DS; Goudreau JL; Parashos SA; Saint-Hilaire MH; Rudolph A; Hare JM; Curhan GC; Ascherio A;
    Neurology; 2019 Oct; 93(14):e1328-e1338. PubMed ID: 31484712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson's disease in Japan.
    Iwaki H; Ando R; Miyaue N; Tada S; Tsujii T; Yabe H; Nishikawa N; Nagai M; Nomoto M
    J Neurol Sci; 2017 Dec; 383():75-78. PubMed ID: 29246629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urate as a predictor of the rate of clinical decline in Parkinson disease.
    Ascherio A; LeWitt PA; Xu K; Eberly S; Watts A; Matson WR; Marras C; Kieburtz K; Rudolph A; Bogdanov MB; Schwid SR; Tennis M; Tanner CM; Beal MF; Lang AE; Oakes D; Fahn S; Shoulson I; Schwarzschild MA;
    Arch Neurol; 2009 Dec; 66(12):1460-8. PubMed ID: 19822770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis.
    Walk D; Nicholson K; Locatelli E; Chan J; Macklin EA; Ferment V; Manousakis G; Chase M; Connolly M; Dagostino D; Hall M; Ostrow J; Pothier L; Lieberman C; Gelevski D; Randall R; Sherman AV; Steinhart E; Walker DG; Walker J; Yu H; Wills AM; Schwarzschild MA; Beukenhorst AL; Onnela JP; Berry JD; Cudkowicz ME; Paganoni S
    Muscle Nerve; 2023 May; 67(5):378-386. PubMed ID: 36840949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease.
    Bhattacharyya S; Bakshi R; Logan R; Ascherio A; Macklin EA; Schwarzschild MA
    Mov Disord; 2016 Mar; 31(3):417-21. PubMed ID: 26805433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Urate Levels Do Not Alter Bone Turnover Markers: Randomized Controlled Trial of Inosine Supplementation in Postmenopausal Women.
    Dalbeth N; Horne A; Mihov B; Stewart A; Gamble GD; Merriman TR; Stamp LK; Reid IR
    Arthritis Rheumatol; 2021 Sep; 73(9):1758-1764. PubMed ID: 33586367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial.
    Simuni T; Fiske B; Merchant K; Coffey CS; Klingner E; Caspell-Garcia C; Lafontant DE; Matthews H; Wyse RK; Brundin P; Simon DK; Schwarzschild M; Weiner D; Adams J; Venuto C; Dawson TM; Baker L; Kostrzebski M; Ward T; Rafaloff G;
    JAMA Neurol; 2021 Mar; 78(3):312-320. PubMed ID: 33315105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.
    Schwarzschild MA; Schwid SR; Marek K; Watts A; Lang AE; Oakes D; Shoulson I; Ascherio A; ; Hyson C; Gorbold E; Rudolph A; Kieburtz K; Fahn S; Gauger L; Goetz C; Seibyl J; Forrest M; Ondrasik J
    Arch Neurol; 2008 Jun; 65(6):716-23. PubMed ID: 18413464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.
    Pagan FL; Hebron ML; Wilmarth B; Torres-Yaghi Y; Lawler A; Mundel EE; Yusuf N; Starr NJ; Anjum M; Arellano J; Howard HH; Shi W; Mulki S; Kurd-Misto T; Matar S; Liu X; Ahn J; Moussa C
    JAMA Neurol; 2020 Mar; 77(3):309-317. PubMed ID: 31841599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
    Jankovic J; Goodman I; Safirstein B; Marmon TK; Schenk DB; Koller M; Zago W; Ness DK; Griffith SG; Grundman M; Soto J; Ostrowitzki S; Boess FG; Martin-Facklam M; Quinn JF; Isaacson SH; Omidvar O; Ellenbogen A; Kinney GG
    JAMA Neurol; 2018 Oct; 75(10):1206-1214. PubMed ID: 29913017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis.
    Nicholson K; Chan J; Macklin EA; Levine-Weinberg M; Breen C; Bakshi R; Grasso DL; Wills AM; Jahandideh S; Taylor AA; Beaulieu D; Ennist DL; Andronesi O; Ratai EM; Schwarzschild MA; Cudkowicz M; Paganoni S
    Ann Clin Transl Neurol; 2018 Dec; 5(12):1522-1533. PubMed ID: 30564619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
    ; Beal MF; Oakes D; Shoulson I; Henchcliffe C; Galpern WR; Haas R; Juncos JL; Nutt JG; Voss TS; Ravina B; Shults CM; Helles K; Snively V; Lew MF; Griebner B; Watts A; Gao S; Pourcher E; Bond L; Kompoliti K; Agarwal P; Sia C; Jog M; Cole L; Sultana M; Kurlan R; Richard I; Deeley C; Waters CH; Figueroa A; Arkun A; Brodsky M; Ondo WG; Hunter CB; Jimenez-Shahed J; Palao A; Miyasaki JM; So J; Tetrud J; Reys L; Smith K; Singer C; Blenke A; Russell DS; Cotto C; Friedman JH; Lannon M; Zhang L; Drasby E; Kumar R; Subramanian T; Ford DS; Grimes DA; Cote D; Conway J; Siderowf AD; Evatt ML; Sommerfeld B; Lieberman AN; Okun MS; Rodriguez RL; Merritt S; Swartz CL; Martin WR; King P; Stover N; Guthrie S; Watts RL; Ahmed A; Fernandez HH; Winters A; Mari Z; Dawson TM; Dunlop B; Feigin AS; Shannon B; Nirenberg MJ; Ogg M; Ellias SA; Thomas CA; Frei K; Bodis-Wollner I; Glazman S; Mayer T; Hauser RA; Pahwa R; Langhammer A; Ranawaya R; Derwent L; Sethi KD; Farrow B; Prakash R; Litvan I; Robinson A; Sahay A; Gartner M; Hinson VK; Markind S; Pelikan M; Perlmutter JS; Hartlein J; Molho E; Evans S; Adler CH; Duffy A; Lind M; Elmer L; Davis K; Spears J; Wilson S; Leehey MA; Hermanowicz N; Niswonger S; Shill HA; Obradov S; Rajput A; Cowper M; Lessig S; Song D; Fontaine D; Zadikoff C; Williams K; Blindauer KA; Bergholte J; Propsom CS; Stacy MA; Field J; Mihaila D; Chilton M; Uc EY; Sieren J; Simon DK; Kraics L; Silver A; Boyd JT; Hamill RW; Ingvoldstad C; Young J; Thomas K; Kostyk SK; Wojcieszek J; Pfeiffer RF; Panisset M; Beland M; Reich SG; Cines M; Zappala N; Rivest J; Zweig R; Lumina LP; Hilliard CL; Grill S; Kellermann M; Tuite P; Rolandelli S; Kang UJ; Young J; Rao J; Cook MM; Severt L; Boyar K
    JAMA Neurol; 2014 May; 71(5):543-52. PubMed ID: 24664227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease.
    Chen X; Umeh CC; Tainsh RE; Feng DD; Maguire M; Zuo F; Rahimian M; Logan R; Wang X; Ascherio A; Macklin EA; Buys ES; Schwarzschild MA;
    EBioMedicine; 2018 Nov; 37():259-268. PubMed ID: 30415890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
    JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting urate to reduce oxidative stress in Parkinson disease.
    Crotty GF; Ascherio A; Schwarzschild MA
    Exp Neurol; 2017 Dec; 298(Pt B):210-224. PubMed ID: 28622913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial.
    Stevens KN; Creanor S; Jeffery A; Whone A; Zajicek J; Foggo A; Jones B; Chapman R; Cocking L; Wilks J; Webb D; Carroll C;
    JAMA Neurol; 2022 Dec; 79(12):1232-1241. PubMed ID: 36315128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study.
    Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):44-52. PubMed ID: 31754882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
    Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):53-61. PubMed ID: 31792640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.